REPROCELL News

17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from January 2021 in Japan. REPROCELL has also launched a new B2C website to promote the Personal iPS service, which is currently only available in Japan.

Continue reading

Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.

Continue reading

Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) are established for future regenerative medicine treatment.

Continue reading

REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal^®.

Continue reading